Weekly Carboplatin/Docetaxel for Recurrent Ovarian/Peritoneal Cancer

This study has been completed.
Aventis Pharmaceuticals
Information provided by (Responsible Party):
University of Wisconsin, Madison
ClinicalTrials.gov Identifier:
First received: September 13, 2005
Last updated: September 30, 2015
Last verified: June 2008
The purpose of this study is to determine the safety and efficacy of this regimen in women with ovarian or peritoneal cancer

Condition Intervention Phase
Ovarian Carcinoma
Primary Peritoneal Carcinoma
Drug: Carboplatin
Drug: Docetaxel
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Evaluation of Weekly Docetaxel in Combination With Weekly Carboplatin in the Treatment of Recurrent Epithelial Ovarian Carcinoma

Resource links provided by NLM:

Further study details as provided by University of Wisconsin, Madison:

Primary Outcome Measures:
  • Safety and Efficacy

Secondary Outcome Measures:
  • QOL

Estimated Enrollment: 36
Study Start Date: August 2002
Study Completion Date: February 2006

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female

Inclusion Criteria:

  • Recurrent ovarian or peritoneal cancer

Exclusion Criteria:

  • No prior chemotherapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00214058

United States, Wisconsin
University of Wisconsin Hospital and Clinics
Madison, Wisconsin, United States, 53792
Sponsors and Collaborators
University of Wisconsin, Madison
Aventis Pharmaceuticals
Principal Investigator: David M Kushner, MD University of Wisconsin, Madison
  More Information

No publications provided

Responsible Party: University of Wisconsin, Madison
ClinicalTrials.gov Identifier: NCT00214058     History of Changes
Other Study ID Numbers: CO 02701
Study First Received: September 13, 2005
Last Updated: September 30, 2015
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Neoplasms, Glandular and Epithelial
Ovarian Neoplasms
Adnexal Diseases
Endocrine Gland Neoplasms
Endocrine System Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Gonadal Disorders
Neoplasms by Histologic Type
Neoplasms by Site
Ovarian Diseases
Urogenital Neoplasms
Antimitotic Agents
Antineoplastic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Tubulin Modulators

ClinicalTrials.gov processed this record on November 25, 2015